Melanoma Clinical Trials in San Diego

Showing 81-100 of 196 trials

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

NCT05909995

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.

MelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)+3 more

Incyte Corporation8 participantsStarted Aug 2023

Los Angeles, California, United States • Orange, California, United States • San Diego, California, United States +5 more locations

COMPLETEDPhase 311 miles

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

Melanoma

Bristol-Myers Squibb906 participantsStarted Mar 2015

Little Rock, Arkansas, United States • La Jolla, California, United States • Los Angeles, California, United States +133 more locations

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Melanoma Trials in Other Cities

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Milademetan in Advanced/Metastatic Solid Tumors

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Other Conditions in San Diego